PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: ...
The WATER IV AS trial aims to assess Aquablation as earlier intervention for men on active surveillance Procept BioRobotics has received a second FDA investigational device exemption (IDE) to allow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results